Final results from the phase 3 CheckMate-9ER trial show that cabozantinib (CABOMETYX) combined with nivolumab (Opdivo) continues to demonstrate...

Bristol Myers Squibb announced that the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for adjuvant treatment of...

Virpax Pharmaceuticals announced positive results from a U.S. Army Institute of Surgical Research (USAISR) study on Probudur™, a non-addictive...

ImmunityBio announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its marketing authorization application for...

Pfizer announced positive Phase 3 TALAPRO-2 trial results for TALZENNA (talazoparib) combined with XTANDI (enzalutamide) in treating metastatic castration-resistant...

Allogene Therapeutics announced positive results from its Phase 1 ALPHA and ALPHA2 clinical trials of cema-cel, an allogeneic CAR...

UCB’s Bimzelx (bimekizumab), a dual IL-17A/IL-17F inhibitor for psoriatic arthritisarthritis (PsA), is demonstrating strong early adoption among rheumatologists just...

BioCardia completed enrollment and dosing in the low-dose cohort of its CardiALLO™ Phase I/II trial. This trial investigates allogeneic...

AskBio, a Bayer subsidiary, has initiated the European arm of its Phase 2 GenePHIT trial for AB-1002, a gene...

NKGen Biotech announced the publication of Phase 1 clinical trial results for troculeucel, an NK cell therapy for Alzheimer’s...